The aim of this preclinical study was to investigate the in vivo biodistribution and tumor targeting potential of the newly synthesized 52Mn-labeled DOTAGA-bevacizumab PET probe in the VEGF-A positive cervix carcinoma tumor-bearing mouse model. Here, VEGFA is linked to neoplasm.